News Sentiment

ATRA sentiment intelligence

Atara Biotherapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 45 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 9.76 Week of 10 Jul 2026
Weighted tone 45/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

-16.2% over one week, -6.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Enterprise value to EBITDA forward of Atara Biotherapeutics Inc – MUN:AT20

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction -16.2% Price reacting lower
Trend fit Trend inactive -6.2% over four weeks
Fair value -31.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 7
Neutral 39
Negative 16

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
ACCESS Newswire 8
TradingView 7
Market source 7
Stock Titan 5
TradingKey 5
Business Wire 5
simplywall.st 3
Investing.com 3

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 16
Regulatory and legal 12
Guidance 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 62
TradingView Direct company coverage

Enterprise value to EBITDA forward of Atara Biotherapeutics Inc – MUN:AT20

The article provides a financial overview of Atara Biotherapeutics Inc (MUN:AT20), specifically focusing on its Enterprise Value to EBITDA forward metric. It indicates that the market is closed with no trades showing, and provides links to various financial data and community too

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 17:11
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Atara Biotherapeutics Inc – MUN:AT20

This article provides financial information for Atara Biotherapeutics Inc (MUN:AT20), specifically focusing on its Enterprise Value to EBIT forward metric. It details that the market is currently closed, with no trades, and offers various financial resources and market data for t

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 10:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Atara Biotherapeutics Inc – MUN:AT20

The article provides a financial snippet for Atara Biotherapeutics Inc (MUN:AT20), specifically focusing on its enterprise value to revenue forward. It appears to be a stub or a section of a larger financial data page on TradingView, indicating no current trades and directing use

Tone
Neutral 50/100
Event
Earnings
Published
12 Jul 2026 21:08
Source
TradingView
ACCESS Newswire Direct company coverage

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Atara Biotherapeutics, Inc. (ATRA) on behalf of investors who purchased shares before May 20, 2024, and continue to hold them. The investigation focuses on whether Atara and its officers engaged in corpo

Tone
Negative 28/100
Event
Regulatory and legal
Published
12 Jul 2026 11:00
Source
ACCESS Newswire
Stock Traders Daily Direct company coverage

Avoiding Lag: Real-Time Signals in (ATRA) Movement

This article analyzes Atara Biotherapeutics Inc. (NASDAQ: ATRA), highlighting its near-term weak sentiment and a mid-channel oscillation pattern. It identifies a significant short setup with an exceptional risk-reward ratio and provides three distinct AI-generated trading strateg

Tone
Negative 29/100
Event
Market update
Published
12 Jul 2026 02:40
Source
Stock Traders Daily
timothysykes.com Direct company coverage

Atara Biotherapeutics Inc. (ATRA) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for Atara Biotherapeutics Inc. (ATRA) stock, showing its current price of $9.94, up $0.30 (3.06%). It also notes that there are currently no analyst ratings or earnings information available for the company. The page features trading guid

Tone
Positive 60/100
Event
Earnings
Published
09 Jul 2026 21:17
Source
timothysykes.com
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Atara Biotherapeutics, Inc. (ATRA) for alleged corporate wrongdoing. The firm encourages investors who purchased Atara securities before May 20, 2024, and continue to hold them, to join the investigation

Tone
Negative 18/100
Event
Regulatory and legal
Published
09 Jul 2026 11:00
Source
ACCESS Newswire
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Atara Biotherapeutics, Inc. (ATRA) concerning potential corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased Atara securities before May 20, 2024, and still hol

Tone
Negative 33/100
Event
Regulatory and legal
Published
08 Jul 2026 11:40
Source
ACCESS Newswire
Stock Titan Direct company coverage

Atara Biotherapeutics (ATRA) interim CFO Kevin Sarney files initial Form 3

Atara Biotherapeutics' interim CFO, Kevin G. Sarney, has filed an initial Form 3, which is a statement of beneficial ownership. This filing identifies him as an officer of the company but reports no transactions or holdings. Form 3 acts as an initial inventory sheet for insiders'

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 19:10
Source
Stock Titan
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) securities who bought shares prior to May 20, 2024, and still hold them. The investigation aims to determine if Atara and its officers or dire

Tone
Negative 20/100
Event
Regulatory and legal
Published
05 Jul 2026 23:41
Source
ACCESS Newswire
Finviz Direct company coverage

ATRA - Atara Biotherapeutics Inc Latest SEC Filings

This article provides a detailed financial overview and key performance indicators for Atara Biotherapeutics Inc (ATRA). It includes market capitalization, income, sales, various financial ratios, insider and institutional ownership, and stock performance metrics. The data is bas

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 10:39
Source
Finviz
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into alleged corporate wrongdoing by Atara Biotherapeutics, Inc. (ATRA) and its officers/directors. Investors who purchased Atara securities before May 20, 2024, and still hold them, are encouraged to contact the f

Tone
Negative 26/100
Event
Regulatory and legal
Published
02 Jul 2026 11:00
Source
ACCESS Newswire
The National Law Review Direct company coverage

ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on behalf of investors who suffered losses between May 20, 2024, and January 9, 2026. The lawsuit alleges that Atara made false and misleading statements rega

Tone
Negative 29/100
Event
Regulatory and legal
Published
01 Jul 2026 08:40
Source
The National Law Review
Stock Traders Daily Direct company coverage

Discipline and Rules-Based Execution in ATRA Response

Quantitative Research Desk provides an analysis of Atara Biotherapeutics Inc. (NASDAQ: ATRA), identifying strong near- and mid-term sentiment but a weak long-term outlook. The report highlights resistance testing and an exceptional risk-reward short setup. It also outlines specif

Tone
Neutral 50/100
Event
Guidance
Published
01 Jul 2026 01:34
Source
Stock Traders Daily
The National Law Review Direct company coverage

ATRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Atara Biotherapeutics, Inc. (NASDAQ:ATRA) due to alleged misstatements regarding manufacturing issues and the integrity of the ALLELE study, making FDA approval unlikely. Investors who purchased Atara

Tone
Negative 28/100
Event
Regulatory and legal
Published
30 Jun 2026 16:39
Source
The National Law Review
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Atara Biotherapeutics, Inc. (ATRA) concerning potential corporate wrongdoing. The firm is encouraging stockholders who purchased Atara securities prior to May 20, 2024, and still hold them, to come forward and

Tone
Negative 28/100
Event
Regulatory and legal
Published
29 Jun 2026 08:40
Source
ACCESS Newswire
marketscreener.com Direct company coverage

Atara Biotherapeutics, Inc.(NasdaqGS:ATRA) dropped from Russell Microcap Value Benchmark Index

Atara Biotherapeutics, Inc. (NasdaqGS:ATRA) has been removed from the Russell Microcap Value Benchmark Index. This news follows a similar announcement on June 28, 2026, regarding its removal from the Russell 3000E Value Benchmark. The company, an allogeneic T-cell immunotherapy f

Tone
Negative 34/100
Event
Market update
Published
29 Jun 2026 08:40
Source
marketscreener.com
TradingView Direct company coverage

Atara Biotherapeutics Inc Actuals & Estimates (GETTEX:AT20)

This article provides an overview of Atara Biotherapeutics Inc (AT20) stock on the GETTEX exchange, including its current price, historical performance, and analyst forecasts. It also details financial actuals and estimates, such as earnings, revenue, net income, market capitaliz

Tone
Positive 66/100
Event
Earnings
Published
28 Jun 2026 15:41
Source
TradingView
Stock Titan Direct company coverage

Atara Biotherapeutics (NASDAQ: ATRA) appoints CRCFO consultant as interim CFO

Atara Biotherapeutics announced leadership changes in its finance organization, with Chief Accounting Officer Yanina Grant-Huerta's employment ending on July 17, 2026. The company appointed Kevin G. Sarney of Charles River CFO, Inc. as interim Chief Financial Officer, Principal F

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 20:40
Source
Stock Titan
TradingView Direct company coverage

Atara Biotherapeutics Inc Actuals & Estimates (NASDAQ:ATRA)

This article provides an overview of Atara Biotherapeutics, Inc. (ATRA) stock, including its current price, historical performance, and analyst forecasts. It also details financial metrics such as earnings per share, revenue, net income, and market capitalization, along with upco

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 09:39
Source
TradingView
TradingView Direct company coverage

ATRA Forecast — Price Target — Prediction for 2027

This article provides a forecast for Atara Biotherapeutics, Inc. (ATRA) stock, including current price, analyst price targets, and historical performance. It also details the company's financials such as recent earnings, revenue, market capitalization, and upcoming earnings dates

Tone
Positive 62/100
Event
Earnings
Published
25 Jun 2026 18:39
Source
TradingView
TradingKey Direct company coverage

Atara Biotherapeutics Inc (ATRA) Valuation: PE, PB & Fair Value Analysis

Atara Biotherapeutics Inc (ATRA) currently holds a valuation score of 7.36, ranking 235 out of 387 in the Biotechnology & Medical Research industry. Its P/E ratio stands at -7.24, showing significant deviation from its recent high and low P/E values. Key valuation metrics like P/

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 18:39
Source
TradingKey
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) securities. The investigation concerns whether Atara and its officers or directors engaged in corporate wrongdoing, specifically for investor

Tone
Negative 29/100
Event
Regulatory and legal
Published
21 Jun 2026 22:09
Source
ACCESS Newswire
TradingKey Direct company coverage

Atara Biotherapeutics Inc (ATRA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Atara Biotherapeutics Inc (ATRA) has an earnings forecast score of 7.50, ranking 286th in its industry. Analysts have an average price target of $17.00 for ATRA, with forecasts ranging from $16.00 to $18.00, suggesting a potential upside of over 42%. Based on 4 analysts, the cons

Tone
Positive 71/100
Event
Earnings
Published
18 Jun 2026 10:10
Source
TradingKey
TradingKey Direct company coverage

Atara Biotherapeutics Inc (ATRA) Institutional Confidence

Atara Biotherapeutics Inc (ATRA) has an institutional shareholding score of 3.00, placing it 193rd in the Biotechnology & Medical Research industry. The institutional shareholding proportion has decreased by 28.53% quarter-over-quarter to 43.48%. Steven Cohen is the largest insti

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 10:10
Source
TradingKey
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for alleged corporate wrongdoing. Shareholders who purchased Atara securities before May 20, 2024, are encouraged to contact the firm to assist with the investig

Tone
Negative 13/100
Event
Market update
Published
18 Jun 2026 00:39
Source
ACCESS Newswire
TradingKey Direct company coverage

Atara Biotherapeutics Inc (ATRA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Atara Biotherapeutics Inc (ATRA)'s dividend history and stock split events. It states that the company has not distributed dividends in the past five years and details several recent merger-related stock splits with a 25-to-1 ratio, all dated

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jun 2026 06:40
Source
TradingKey